Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T5383 | D3-βArr | 662164-09-2 | 99.43% |
|
D3-βArr (NCGC00379308) is a positive allosteric modulator for thyrotropin receptor (TSHR), which initiates translocation of β-Arr 1 (EC50: 11.6 μM) by direct TSH... | ||||
T12192 | NCGC00229600 | 1338824-20-6 | 99.27% |
|
NCGC00229600 is an allosteric inverse thyrotropin receptor (TSHR) agonist. NCGC00229600 inhibits both TSH and stimulating antibody activation of TSHRs endogenous... | ||||
T13216 | TSHR antagonist S37 | 1217616-61-9 | 98.35% |
|
TSHR antagonist S37 is a selective and competitive antagonist of the thyrotropin receptor (TSHR). | ||||
T12073 | ML-109 | 1186649-91-1 | 98.14% |
|
ML-109 is a potent agonist of thyroid stimulating hormone receptor (TSHR) (EC50 of 40 nM) | ||||
T29087 | VA-K-14 hydrochloride | 1171341-19-7 | 98.01% |
|
VA-K-14 hydrochloride(VAK14 HCl) is a selective thyrotropin receptor (TSHR) antagonist (IC50= 12.3 μM) that inhibits TSHR stimulation by serum and monoclonal TSH... | ||||
T76727 | Teprotumumab | 1036734-93-6 | 98% |
Teprotumumab
|
Teprotumumab is a human monoclonal antibody that blocks the IGF-1 receptor (IGF-1R). Teprotumumab binds to the extracellular α-subunit domain ligand of IGF-1R. T... | ||||
T16106 | ML224 | 1338824-21-7 | 98% |
|
ML224 (NCGC00242364) is a TSHR antagonist for the treatment of Graves' orbital disease and Graves' hyperthyroidism. | ||||
T16403 | Org41841 | 301847-37-0 | 98% |
|
Org41841 is an agonist of luteinising hormone/chorionic gonadotropin receptor and thyroid stimulating hormone receptor (EC50s: 0.2 and 7.7 μM, respectively) and ... |